US Markets

Xeris Pharma's low blood sugar treatment wins FDA approval

The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc's glucagon pen that aims to treat severely low sugar levels in diabetes patients, the drugmaker said on Tuesday.

By Aakash B

Sept 10 (Reuters) - The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc's XERS.O glucagon pen that aims to treat severely low sugar levels in diabetes patients, the drugmaker said on Tuesday.

The condition, called hypoglycemia, can cause acute cognitive impairment. A mild or moderate fall in sugar levels, when left untreated, can result in cardiovascular disease, seizure, coma, and even death.

Gvoke, Xeris' glucagon pen is an pre-filled device with liquid stable form of glucagon. It won approval for use in diabetes patients, aged 2 years and above.

Long-term use of insulin can sometimes lead to side effects, including hypoglycemia. Severe hypoglycemia typically occurs in diabetics on insulin treatment.

There are 5.6 million type 1 and type 2 diabetics who are taking insulin and anyone on insulin should have glucagon handy, Chief Executive Officer Paul Edick said.

"Just about everyone who is a diabetic is going to have frequent low blood sugar, most of them once or twice a year are going to have a severe episode that needs rescue."

Eli Lilly and Co's LLY.N Baqsimi was approved to treat hypoglycemia by the U.S. FDA in July, making it the first approved non-injectable glucagon therapy for the emergency treatment of the condition.

Glucagon is a hormone produced by the pancreas that is responsible for raising the concentration of glucose and fatty acids in the bloodstream.

Injectable form of glucagon, standard of care for treating hypoglycemia, has been approved for use in the United States for several decades.

(Reporting by Aakash Jagadeesh Babu and Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)

((Aakash.B@thomsonreuters.com; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Reuters Messaging: Aakash.B.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest US Markets Videos

    #TradeTalks: How Investors Start to Position Themselves in front of the Election

    WealthWise Financial CEO Loreen Gilbert joins Jill Malandrino on Nasdaq #TradeTalks to discuss what she is watching in the markets as investors start to position themselves in front of the election.

    Sep 10, 2020

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More